All In Biotech

Drug Trial Radar · NCT05904691

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Safety and Tolerability of Single Ascending Doses and Multiple Repeat Doses of OCU-10-C-110 for Injection in Study Participants With Neovascular Age-related Macular Degeneration (nAMD)

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Nov 1, 2023

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Ocugenix CorporationIndustry
Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • OCU-10-C-110 for InjectionDrug

    OCU-10-C-110 for Injection in one of 3 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular safety - AETime frame: Cohort A - 8 weeks; Cohort B - 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Raj K. Maturi, M.D., P.C.

    Carmel, Indiana

  • Retina Research Institute of Texas

    Abilene, Texas

  • Strategic Clinical Research Group LLC

    Willow Park, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.